跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
LAZCLUZE 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
LAZCLUZE 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Approved
STANDARD
LAZCLUZE 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Janssen-Cilag International N.V
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jan 29, 2025
Approval ID
40d9ccfb779139c9
Company
Janssen-Cilag International N.V
Type
Standard
Approval Details
Approval Id
40d9ccfb779139c9
Drug Cima Aemps Name
LAZCLUZE 240 MG COMPRIMIDOS RECUBIERTOS CON PELICULA
Register Number
1241886005
Holder Company Name
Janssen-Cilag International N.V
Marketing Company Name
Janssen Cilag S.A.
Holder Company Detail Path
/organization/janssen-cilag-international-nv
Authorization Date
2025-01-29
Dosage Form
COMPRIMIDO RECUBIERTO CON PELÍCULA
Dose
240 mg
Route Of Administration
VÍA ORAL
Prescription Type
Diagnóstico Hospitalario
Commercialized
Yes
Company Name
Janssen-Cilag International N.V
Company Detail Path
/organization/janssen-cilag-international-nv
Company Information
Pharmaceutical Company Name
Janssen-Cilag International NV
Country Name
Belgium
Active Ingredients
LAZERTINIB
240 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jan 29, 2025
Approval ID
40d9ccfb779139c9
Type
Standard
Back to CIMA-AEMPS Approvals
